Organogenesis Announces Publication of Peer-Reviewed PREPARE Trial Results Demonstrating Clinical Benefit of PuraPly®AM for Hard-to-Heal Diabetic Foot UlcersGlobeNewsWire · Oct 12, 2026
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026GlobeNewsWire · Oct 12, 2026
These beaten-down stocks could bounce back in January, if history is any guideMarket Watch · Sep 21, 2026
BlackRock Inc. Purchases Shares of 7,249,528 Organogenesis $ORGODefense World · Sep 4, 2026
Organogenesis Q2 Earnings Call HighlightsMarketBeat · Aug 7, 2026
Organogenesis Holdings Inc. (ORGO) Q2 2026 Earnings Call TranscriptSeeking Alpha · Aug 7, 2026Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.35 | -$0.71 | Miss |
| May 7, 2026 | -$0.29 | -$0.37 | Miss |
| Feb 26, 2026 | $0.22 | $0.31 | Beat |
| Nov 6, 2025 | $0.21 | $0.18 | Miss |
| Aug 7, 2025 | $0.07 | -$0.09 | Miss |
| May 8, 2025 | $0.04 | -$0.13 | Miss |